MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
MediWound Ltd. - Ordinary Shares (MDWD)
Last mediwound ltd. - ordinary shares earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mediwound.com/press-releases
Company Research
Source: GlobeNewswire
YAVNE, Israel, June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the enrollment target of patients for an interim assessment of its EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs) has been achieved, and interim assessment is expected by the end of July 2021. The pre-defined interim assessment is for futility analysis and potential sample size adjustment. This study, which is targeted to enroll a total of 120 patients by year-end 2021, is designed to assess the safety and efficacy of EscharEx compared to gel vehicle (placebo control) and non-surgical standard-of-care (either enzymatic or autolytic debridement). “We are very pleased to reach this important clinical milestone, and we look forward to the interim assessment next month,” said Sharon Malka, Chief Executive Off
Show less
Read more
Impact Snapshot
Event Time:
MDWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDWD alerts
High impacting MediWound Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MDWD
News
- MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences [Yahoo! Finance]Yahoo! Finance
- MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care ConferencesGlobeNewswire
- MediWound Ltd. (NASDAQ: MDWD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- What Makes MediWound (MDWD) a Good Fit for 'Trend Investing' [Yahoo! Finance]Yahoo! Finance
- MediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
MDWD
Earnings
- 3/21/24 - Beat
MDWD
Analyst Actions
- 3/22/24 - HC Wainwright
MDWD
Sec Filings
- 3/21/24 - Form 20-F
- 3/21/24 - Form 6-K
- 2/14/24 - Form SC
- MDWD's page on the SEC website